Fig. 4From: Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatmentA Schematic showing the hNVs consist of engineered SαV-C-NVs, M1-NVs, and P-NVs. B Schematic showing the hNVs efficiently interact with CTCs in the blood, accumulate in the post-surgical tumor bed, repolarize TAMs towards M1 phenotype, and block the CD47-SIRPα ‘don’t eat me’ pathway, thus promoting macrophage phagocytosis of cancer cells, as well as boosting antitumor T cell immunity. Average C tumor growth kinetics in 4T1 tumor groups. D Metastasis rates after indicated treatments. Average E tumor growth kinetics in B16F10 tumor groups. F Numbers of lung metastatic foci after different treatments. Adapted with permission from [81], copyright © 2022 Springer Nature LimitedBack to article page